Cytokinetics Inc (CYTK)
55.06
+0.66
(+1.22%)
USD |
NASDAQ |
Jul 05, 14:26
Cytokinetics SG&A Expense (Annual): 173.61M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 173.61M |
December 31, 2022 | 177.98M |
December 31, 2021 | 96.80M |
December 31, 2020 | 52.82M |
December 31, 2019 | 39.61M |
December 31, 2018 | 31.28M |
December 31, 2017 | 36.47M |
December 31, 2016 | 27.82M |
December 31, 2015 | 19.67M |
December 31, 2014 | 17.27M |
December 31, 2013 | 15.09M |
December 31, 2012 | 12.43M |
Date | Value |
---|---|
December 31, 2011 | 13.59M |
December 31, 2010 | 14.20M |
December 31, 2009 | 15.63M |
December 31, 2008 | 15.08M |
December 31, 2007 | 16.72M |
December 31, 2006 | 15.24M |
December 31, 2005 | 12.98M |
December 31, 2004 | 11.99M |
December 31, 2003 | 8.972M |
December 31, 2002 | 6.953M |
December 31, 2001 | 5.897M |
December 31, 2000 | 3.39M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
39.61M
Minimum
2019
177.98M
Maximum
2022
108.16M
Average
96.80M
Median
2021
SG&A Expense (Annual) Benchmarks
Amgen Inc | 6.179B |
Gilead Sciences Inc | 6.09B |
Insmed Inc | 344.50M |
Eli Lilly and Co | 6.941B |
Avinger Inc | 14.10M |